Comparative Pharmacology
Head-to-head clinical analysis: PALYNZIQ versus VPRIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PALYNZIQ versus VPRIV.
PALYNZIQ vs VPRIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PALYNZIQ (pegvaliase-pqpz) is a recombinant phenylalanine ammonia lyase conjugated to polyethylene glycol. It converts phenylalanine to trans-cinnamic acid and ammonia, reducing blood phenylalanine levels in patients with phenylketonuria.
VPRIV (velaglucerase alfa) is a recombinant form of human lysosomal glucocerebrosidase that hydrolyzes glucocerebroside to glucose and ceramide, replacing the deficient enzyme in Gaucher disease.
2.4 mg subcutaneously once daily.
60 U/kg intravenously every 2 weeks over 4 hours.
None Documented
None Documented
Approximately 60–80 hours (terminal half-life); supports weekly dosing regimen.
Terminal elimination half-life is approximately 30 minutes (range 15-60 minutes) in Gaucher disease patients, necessitating intravenous infusion over 1-2 hours every other week.
Renal (predominantly as intact pegylated enzyme); less than 5% fecal. No active metabolites.
Primarily metabolized via peptide hydrolysis; elimination is predominantly non-renal. Renal excretion accounts for <5% of the dose as intact drug. Fecal elimination of metabolites is negligible.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy